CDKN2A and hepatocellular carcinoma: CDKN2A could inhibit the tumor-promoting behavior of CDK4/6, and given that the CDKN2A alteration is frequent in HCC, CDK4/6 inhibitors are presently being tested in advanced HCC [53].